JP2003532640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003532640A5 JP2003532640A5 JP2001574119A JP2001574119A JP2003532640A5 JP 2003532640 A5 JP2003532640 A5 JP 2003532640A5 JP 2001574119 A JP2001574119 A JP 2001574119A JP 2001574119 A JP2001574119 A JP 2001574119A JP 2003532640 A5 JP2003532640 A5 JP 2003532640A5
- Authority
- JP
- Japan
- Prior art keywords
- apomorphine
- patient
- norapomorphine
- administering
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 16
- 229960004046 apomorphine Drugs 0.000 claims 14
- 238000000034 method Methods 0.000 claims 8
- MHPQCGZBAVXCGA-GFCCVEGCSA-N (6ar)-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol Chemical compound N1CCC2=CC=CC3=C2[C@H]1CC1=CC=C(O)C(O)=C13 MHPQCGZBAVXCGA-GFCCVEGCSA-N 0.000 claims 7
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- -1 glucuronates Chemical class 0.000 claims 2
- 150000002373 hemiacetals Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19565000P | 2000-04-07 | 2000-04-07 | |
| US60/195,650 | 2000-04-07 | ||
| PCT/US2001/040393 WO2001076602A1 (en) | 2000-04-07 | 2001-03-29 | Apomorphine derivatives and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003532640A JP2003532640A (ja) | 2003-11-05 |
| JP2003532640A5 true JP2003532640A5 (enExample) | 2005-05-26 |
Family
ID=22722192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001574119A Withdrawn JP2003532640A (ja) | 2000-04-07 | 2001-03-29 | アポモルヒネ誘導体及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6506765B2 (enExample) |
| EP (1) | EP1284735A4 (enExample) |
| JP (1) | JP2003532640A (enExample) |
| KR (1) | KR20030036157A (enExample) |
| CN (1) | CN1471395A (enExample) |
| AU (1) | AU2001255818A1 (enExample) |
| BG (1) | BG107217A (enExample) |
| BR (1) | BR0109515A (enExample) |
| CA (1) | CA2405419A1 (enExample) |
| CZ (1) | CZ20023637A3 (enExample) |
| HU (1) | HUP0301773A3 (enExample) |
| IL (1) | IL151614A0 (enExample) |
| MX (1) | MXPA02009904A (enExample) |
| NO (1) | NO20024806D0 (enExample) |
| PL (1) | PL361672A1 (enExample) |
| SK (1) | SK15772002A3 (enExample) |
| WO (1) | WO2001076602A1 (enExample) |
| ZA (1) | ZA200207489B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
| SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| JP2005503425A (ja) * | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| JP2005526790A (ja) * | 2002-03-19 | 2005-09-08 | ミシェル ホリック | アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法 |
| WO2004069167A2 (en) * | 2003-01-31 | 2004-08-19 | Nastech Pharmaceutical Company Inc. | Method and compositions for treating male infertility |
| BRPI0409380A (pt) * | 2003-04-14 | 2006-04-18 | Vectura Ltd | composições farmacêuticas |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
| ES2399763T3 (es) | 2005-10-12 | 2013-04-03 | Unimed Pharmaceuticals, Llc | Gel de testosterona mejorado y método de utilización |
| GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| US10729710B2 (en) | 2017-11-24 | 2020-08-04 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| EP3972959A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| US12319710B2 (en) | 2019-05-21 | 2025-06-03 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's diseases |
| WO2020234274A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| EP3972600A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| EP0865789B1 (en) | 1993-03-26 | 2005-03-16 | Franciscus Wilhelmus Henricus Maria Merkus | Pharmaceutical compositions for intranasal administration of dihydroergotamine |
| DE10199068I2 (de) | 1994-04-22 | 2004-05-06 | Pentech Pharmaceuticals Inc | Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion. |
| US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5888534A (en) | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| PT914097E (pt) | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
| GB9700878D0 (en) | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
| US5925629A (en) * | 1997-10-28 | 1999-07-20 | Vivus, Incorporated | Transurethral administration of androgenic agents for the treatment of erectile dysfunction |
| EP1035833B1 (en) | 1997-12-02 | 2005-08-31 | Archimedes Development Limited | Compositions for nasal administration |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| WO1999066909A2 (en) * | 1998-06-22 | 1999-12-29 | Univ Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| IT1299566B1 (it) * | 1998-07-17 | 2000-03-16 | Ifi Istituto Farmacoterapico I | Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina |
| US5994363A (en) | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
| JP2002544221A (ja) * | 1999-05-13 | 2002-12-24 | ユニハート コーポレーション | アポコデインおよび／またはその誘導体を含んでなる医薬組成物 |
-
2001
- 2001-03-29 JP JP2001574119A patent/JP2003532640A/ja not_active Withdrawn
- 2001-03-29 HU HU0301773A patent/HUP0301773A3/hu unknown
- 2001-03-29 PL PL01361672A patent/PL361672A1/xx not_active Application Discontinuation
- 2001-03-29 CN CNA01815168XA patent/CN1471395A/zh active Pending
- 2001-03-29 CA CA002405419A patent/CA2405419A1/en not_active Abandoned
- 2001-03-29 IL IL15161401A patent/IL151614A0/xx unknown
- 2001-03-29 CZ CZ20023637A patent/CZ20023637A3/cs unknown
- 2001-03-29 KR KR1020027013436A patent/KR20030036157A/ko not_active Withdrawn
- 2001-03-29 SK SK1577-2002A patent/SK15772002A3/sk not_active Application Discontinuation
- 2001-03-29 MX MXPA02009904A patent/MXPA02009904A/es unknown
- 2001-03-29 WO PCT/US2001/040393 patent/WO2001076602A1/en not_active Ceased
- 2001-03-29 US US09/821,236 patent/US6506765B2/en not_active Expired - Fee Related
- 2001-03-29 BR BR0109515-3A patent/BR0109515A/pt not_active IP Right Cessation
- 2001-03-29 AU AU2001255818A patent/AU2001255818A1/en not_active Abandoned
- 2001-03-29 EP EP01929027A patent/EP1284735A4/en not_active Withdrawn
-
2002
- 2002-09-18 ZA ZA200207489A patent/ZA200207489B/xx unknown
- 2002-10-04 NO NO20024806A patent/NO20024806D0/no not_active Application Discontinuation
- 2002-10-24 BG BG107217A patent/BG107217A/bg unknown